乙型肝炎肝硬化患者血脂变化的临床意义

目的探讨乙型肝炎肝硬化患者血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)及极低密度脂蛋白(VLDL-C)的临床意义。方法回顾性分析浙江大学医学院附属第一医院120例乙型肝炎肝硬化患者临床资料,同时选用我院30例健康体检者临床资料为正常对照。结果与正常体检者相比,乙型肝硬化患者血脂水平明显降低(P0.05),TC、TG、HDL-C、LDL-C水平与白蛋白、胆碱酯酶水平正相关(P0.01),TC、TG、LDL-C水平与凝血酶原时间、MELD分级负相关(P0.01)。结论乙型肝硬化患者血脂水平明显降低,血脂水平与乙肝肝硬化患者肝功能损害明显相关。     

乙型肝炎肝硬化患者血清sICAM-1、IL-6、IL-18及TNF-α水平的表达及临床意义

目的:检测乙型肝炎肝硬化患者血清可溶性细胞间黏附分子-1(s ICAM-1)、白细胞介素-6(IL-6)、白细胞介素-18(IL-18)及肿瘤坏死因子-α(TNF-α)水平,并探讨其临床意义。方法:选取2017年1月至2019年6月我院收治的乙型肝炎肝硬化患者82例作为研究组,同期健康体检者80例作为对照组。比较研究组和对照组及不同Child-Pugh分级乙型肝炎肝硬化患者血清s ICAM-1、IL-6、IL-18、TNF-α、肝功能指标血浆谷丙氨酸氨基转移酶(ALT)、白蛋白(ALB)水平,并分析各指标之间的相关性。结果:研究组血清s ICAM-1、IL-6、IL-18、TNF-α和血浆ALT水平分别为(820.78±85.73)ng/mL、(41.71±13.24)ng/mL、(119.85±45.56)pg/mL、(52.23±22.24)ng/L、(155.20±56.27)U/L,显著高于对照组的(175.51±41.82)ng/mL、(6.67±2.23)ng/mL、(68.71±23.24)pg/mL、(5.65±1.28)ng/L、(15.65±5.23)U/L(P0.05),血浆ALB水平显著低于对照组[(27.69±4.32)g/L vs(45.16±5.65)g/L](P0.05)。随Child-Pugh分级的升高,乙型肝炎肝硬化患者血清s ICAM-1、IL-6、IL-18、TNF-α和血浆ALT水平逐渐升高,血浆ALB水平逐渐降低(P0.05)。乙型肝炎肝硬化患者血清s ICAM-1、IL-6、IL-18及TNF-α水平与血浆ALT水平呈正相关(P均0.05),与血浆ALB水平呈负相关(P均0.05),乙型肝炎肝硬化患者血清s ICAM-1与IL-6、IL-18及TNF-α呈正相关(P均0.05)。结论:乙型肝炎肝硬化患者血清s ICAM-1、IL-6、IL-18、TNF-α水平异常升高,与Child-Pugh分级和肝功能有关,检测血清s ICAM-1、IL-6、IL-18、TNF-α可能为乙型肝炎肝硬化的诊断和病情严重程度的判断提供依据。     

血清胱抑素C 与乙型肝炎性肝硬化肝功能损害程度的相关性分析

目的:探讨血清胱抑素C(Cys C)与乙型肝炎性肝硬化患者肝功能损伤程度的相关性分析。方法:将98例乙型肝炎性肝硬化患者按照肝功能分级的Child-Pugh评分将分为A组(Child A级,n=45例)、B组(Child B级,n=33例)、C组(Child C级,n=20例),同期选取本院门诊正常健康体检者为对照组,检测所有受试者的血清Cys C水平,比较各种之间相关指标的差异。结果:A组、B组、C组、对照组丙氨酸氨基转移酶(ALT)、天门冬氨酸转移酶(AST)、血清白蛋白(ALB)、血清Cys C及血清Cys C阳性率均有统计学差异(P0.05),C组血清Cys C、血清Cys C阳性率高于对照组(P0.05)、A组、B组,而B组高于对照组、A组(P0.05);血清Cys C阳性组与阴性组中含有Child A级、Child B级、Child C级患者的构成比具有统计学意义(P0.05),Cys C阳性组中的Child C级患者比例高于阴性组(P0.05);血清Cys C与Child-Pugh评分呈正相关(P0.05);Child-Pugh评分、ALT、AST与患者血清Cys C阳性呈正相关(P0.05);而ALB则与其呈负相关(P0.05);结论:乙型肝炎性肝硬化患者血清Cys C水平与肝功能损伤程度呈一定相关性,早期检测血清Cys C水平对于评估乙型肝炎性肝硬化患者的肝功能损害具有一定的临床意义。     

16层螺旋CT灌注成像对肝硬化血流状态的评估及与肝硬化程度的相关性研究

目的:探讨16层螺旋CT灌注成像对肝硬化血流状态的评估价值及其与肝硬化程度的相关性。方法:选取2014年1月至2016年1月于我院接受诊治的肝硬化患者126例作为肝硬化组,根据Child-Pugh分级分为A组(Child A级,n=35例)、B组(Child B级,n=50例)、C组(Child C级,n=41例)。另选取同期于我院接受体检的健康人员100例作为对照组。应用16层螺旋CT对受试者肝脏、脾脏、主动脉以及门静脉的层面进行CT动态增强扫描,对比CT灌注参数,采用Pearson相关性分析分析CT灌注参数与肝硬化病情严重程度的关系。结果:肝硬化组肝动脉灌注量(HAP)、肝动脉灌注指数(HPI)、肝脏血流量(TBV)以及平均通过时间(MTT)均明显高于对照组,而门静脉灌注量(PVP)、总肝灌注量(TLP)均明显低于对照组(P0.05)。A组患者HAP、HPI均明显高于C组,而PVP与TLP均明显低于C组,差异有统计学意义(P0.05);两组TBV、MTT比较无统计学差异(P0.05);而A组与B组相比以及B组与C组相比,各项CT灌注参数均无统计学差异(P0.05)。肝硬化患者病情严重程度与HAP、HPI均呈正相关关系(P0.05),而与PVP、TLP均呈负相关关系(P0.05)。结论:16层螺旋CT灌注成像对肝硬化血流状态具有一定的评估价值,且CT灌注参数的水平变化与肝硬化患者病情严重程度存在密切相关。     

自体干细胞移植治疗失代偿期肝硬化的疗效及对肝脏储备功能、血清LPS、HGF水平的影响

目的:探讨自体干细胞移植治疗失代偿期肝硬化的疗效及对肝脏储备功能、血清内毒素(LPS)、肝细胞生长因子(HGF)水平的影响。方法:选择2015年9月至2017年9月我院接诊的86例失代偿期肝硬化患者作为本研究对象,通过随机数表法将其分为观察组和对照组,每组43例。对照组给予失代偿期肝硬化常规综合治疗,观察组在对照组基础上进行自体干细胞移植治疗。比较两组治疗前、治疗12周后实验室指标、终末期肝病模型系统评分(MELD)、血清LPS、HGF水平的变化以及不良反应的发生情况。结果:治疗后,两组丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBil)水平均明显低于治疗前,白蛋白(ALB)较治疗前显著升高(P0.05),观察组ALT、AST、TBil均明显低于对照组,ALB水平明显高于对照组[(45.60±4.12)U/L vs.(56.84±6.20)U/L,(57.45±5.01)U/L vs.(68.99±6.84)U/L,(36.53±3.45)g/L vs.(30.42±2.89)g/L,(50.23±4.83)μmol/L vs.(62.30±6.76)μmol/L](P0.05);治疗后,两组MELD评分较治疗前显著降低(P0.05),观察组MELD评分明显低于对照组[(21.89±2.74)分vs(27.84±3.51)分](P0.05);治疗后,两组血清LPS较治疗前显著降低,HGF较治疗前显著升高(P0.05),观察组血清LPS明显低于对照组,HGF明显比对照组高[(0.43±0.05)ng/mLvs(0.60±0.09)ng/mL,(389.56±27.40)pg/mL vs(301.23±22.30)pg/mL](P0.05)。对照组和观察组治疗期间不良反应总发生率分别为8.89%(4/43)、13.95%(6/43),差异无统计学意义(P0.05)。结论:自体干细胞移植治疗失代偿期患者可明显改善肝功能、肝脏储备功能及血清LPS、HGF的表达,且安全性高。     

抗病毒治疗后慢性乙型重型肝炎预后分析

目的分析慢性乙型重型肝炎抗病毒后影响预后的因素,探讨慢性乙型重型肝炎治疗策略。方法通过回顾性观察153例慢性乙型重型肝炎的临床资料,包括年龄、性别、白蛋白(ALB)、总胆红素(TB)、凝血酶原时间(PT)、甲胎蛋白(AFP)、胆碱酯酶(CHE)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、乙肝病毒核酸(HBV DNA)载量、是否存在肝硬化和是否存在并发症等情况,采用Cox比例风险模型对可能影响其预后的因素进行单因素和多因素回归分析。结果其中年龄、TB、PT、是否存在肝硬化、是否存在并发症是影响预后的独立因素。结论年龄、TB、PT、是否存在肝硬化、是否存在并发症对患者的预后有相关。     

血小板输注治疗肝硬化的临床疗效观察

目的:观察血小板灌注治疗对肝硬化患者肝功能的影响。方法:选择10名有血小板减少(血小板计数在50,000至100,000/μl)表现的肝硬化患者(Child-Pugh分级分别为A级或者B级),每周给予10个单位血小板输注治疗,疗程共12周,在给予最后一次治疗后坚持随访9个月。在血小板输注治疗结束后1周、1个月、3个月以及9个月时,应用腹部超声检测腹水、CT观察肝脏肿瘤及肝脏体积并检测患者的肝功能指标,如血清白蛋白、血清胆碱酯酶、谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素以及凝血酶原激活时间。结果:2名患者由于皮肤瘙痒中断血小板输注治疗,2名患者治疗后随访丢失,最后共6名患者的数据纳入研究。在接受完最后一次血小板输注治疗后,6名患者的血小板计数无显著提高。最后一次血小板输注治疗后1个月和3个月复查时,患者的血清白蛋白水平显著升高。治疗后1周,3个月以及9个月时,患者血清胆碱酯酶在均显著增加。结论:尽管血小板输注治疗对一部分患者存在不良反应,但其可显著提高肝硬化患者的一些肝功能指标,可以作为临床治疗肝硬化的新方法深入研究。     

婴儿肝炎综合征甲状腺素与Child-Pugh分级的关系

目的:肝脏是甲状腺激素降解、排泄及转化的场所,参与甲状腺结合球蛋白的合成.肝脏及肝脏疾病与甲状腺激素关系方面的文献很多,但有关婴儿肝炎综合征(infantile hepatitis syndrome,IHS)甲状腺素水平的报道很少.本文研究IHS患儿血清甲状腺素水平与Child-Pugh肝功能分级的关系,探讨甲状腺素水平对于指导肝功能的分级、评价肝脏储备功能及其预后的临床意义.方法:收集住院的IHS患儿38例,选择20例健康儿作为正常对照组.应用放射免疫法检测各组血清促甲状腺素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平.检测IHS患儿血清白蛋白(ALB)、总胆红素(TBIL)、凝血酶原时间(PT),并记录腹水、肝性脑病等临床情况,按成人Child-Pugh分级标准,将患儿分为A、B、C三级,并将Child-Pugh积分与其甲状腺功能各指标做相关性分析.结果:1、IHS组患儿血清FT3、FT4水平显著低于正常对照组(P＜0.05),TSH水平高于正常对照组水平(P＜0.05);FT3、FT4水平随Child-Pugh积分增加而下降,A、B、C三级组间比较有显著性差异(P＜0.05);TSH水平在三级组间无统计学差异(P＞0.05).2、HIS患儿的血清FT3、FT4水平与Child-Pugh积分呈负相关(r=-0.619～-0.80,P＜0.01),与TSH无相关性(P＞0.05).结论:本研究结果显示婴儿肝炎综合征患儿的血清FT3、FT4水平降低,且与其肝脏受损程度有明显的相关性,因此检测血清FT3、FT4水平,对正确评估婴儿肝炎综合征病情严重程度及其预后具有重要的参考价值.     

肝硬化患者肝脏门静脉血流与肝叶萎缩之间关系的研究

目的:探讨肝硬化患者肝脏右叶、左叶体积变化,检测肝硬化患者门静脉血流情况,分析二者之间的关系,以及门静脉血流与肝功能之间关系。方法:本研究纳入54例肝硬化患者和40例正常人,采用超声多普勒方法分析这些受试者的肝脏体积和门静脉主干及左右分支的内径、血流速、流量数据,并通过静脉血检测白蛋白、胆红素、胆碱酯酶水平等评估患者肝功能水平。结果:肝硬化组平均年龄46.3岁,男性32例,其中child A级患者16例,child B级患者27例,child C级患者11例;正常对照组平均年龄41.8岁,男性24例。肝硬化组患者右左肝叶之比明显低于正常对照组(p<0.05),门静脉内径和血流量明显高于正常对照组(p<0.05).随着child分级升高,门静脉血流量也明显升高。肝硬化组门静脉右支血流量明显低于左支血流量(p<0.05);此外肝硬化患者门静脉右支和左支血流量之比明显低于正常人群门静脉右左支之比(p<0.05);而且肝硬化患者门静脉右左支血流量之比与右左肝叶具有明显的相关性与右左肝叶之比具有明显的相关性(r=0.64,p<0.05)。结论:评估肝硬化病人门静脉血流情况,对于判断肝脏病理变化程度,评价治疗效果,以及选择治疗方案方面都具有重要的临床价值     

60例活动性肝硬变患者血清载脂蛋白AI与B的临床研究

目的：为了探讨活动性肝硬变患者的血清载脂蛋白AI（APOAI）、载脂蛋白B（APOB）与肝细胞损害的严重程度及其预后的关系。方法：采和速度比浊法检测60例活动性肝硬变患者的血清APOAI、APOB水平,并与其他肝脏生化试验进行比较。结果：活动肝硬变代偿性与失代偿性两组APOAI,APOB均有着显著性差异（P＜0．01,P＜0．05）。活动性肝硬变患者的APOAI与总胆红素（TB）、凝血酶原时间（PT）呈负相关性（P＜0．01,P＜0．01,与白蛋白（ALB）,胆碱酯酶（CHE）、纤维蛋白原（FIB）呈显著正相关性（P＜0．01,P＜0．01,P＜0．05）。APOX仅与FIB呈显著相关性（P＜0．05）,好转组与死亡组两组APOAI有显著性差异（P＜0．05）,APOB无显著性差异,结论：检测活动性肝硬变患者血清APOAI,APOB水平有助于判断肝硬变的严重程度,且APOAI比APOB更敏感、可靠。     

Level of nitrated proteins in the plasma,platelets and liver of patients with liver cirrhosis

Abstract

Over-expression of nitric oxide synthase (NOS) and nitric oxide (NO) formation are associated with the pathogenesis of liver cirrhosis. NO-related stress alters the functions of biomolecules, especially proteins, probably as a result of nitration. The aim of this study was to assess the level of protein nitration and its correlation with the severity of the disease. Liver cirrhosis patients with different grades of severity (grades A, B, and C according to the Child–Pugh classification) were enrolled in this study. Nitroprotein content, arginine, citrulline, NO in terms of total nitrite, nitrosothiol (RSNO) and protein carbonyls were measured in blood. Immunohistochemical detection of nitroprotein was carried out in liver sections of cirrhosis patients. A significant elevation in the levels of serum and platelet arginine, arginase, citrulline, plasma, and platelet nitroproteins, RSNO, total nitrite, protein carbonyls and also a significant amount of nitrated proteins by immunohistochemical detection in tissue were observed in cirrhosis patients. The alterations were highly significant in grade C patients with bleeding complications when compared to those of grade B and A patients. In platelets, both cytosolic and cytoskeletal proteins were found to be nitrated significantly. The level of nitrite seems to have positive correlation with the level of nitroproteins in different grades of cirrhosis. The level of nitroproteins in plasma, platelets and liver tissue can be correlated with the severity of liver cirrhosis.     

Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide that has been found to reduce liver inflammation and protect liver from steatosis. We aimed to measure the level of plasma PACAP in patients with liver cirrhosis and to correlate its level with disease severity and laboratory parameters. 113 patients with clinically diagnosed liver cirrhosis and 110 healthy individuals were selected. Child–Pugh score was performed to evaluate disease severity. Liver biopsy was performed using the Knodell modified histology activity index (KmHAI). The L3 skeletal muscle index (L3SMI) was calculated to evaluate the nutrition status. Plasma PACAP concentrations were detected using ELISA. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the sensitivity and specificity of PACAP for detecting the severity of liver cirrhosis. Plasma PACAP levels were found to be significantly downregulated in patients with liver cirrhosis compared with healthy controls. The case group included 38 Child–Pugh A patients, 39 Child–Pugh B patients, and 36 Child–Pugh C patients. Cirrhosis patients with Child–Pugh C had significantly lower plasma PACAP levels compared with those with Child–Pugh B and A. Cirrhosis patients with Child–Pugh B demonstrated markedly decreased plasma PACAP concentrations compared with those with Child–Pugh A. ROC curve analysis indicated that low level of plasma PACAP may act as a potential indicator for disease progression of liver cirrhosis determined by Child–Pugh classification at both compensation stage (Child–Pugh A developed to Child–Pugh B) and decompensation stage (Child–Pugh B developed to Child–Pugh C).In addition, plasma PACAP levels were inversely associated with KmHAI and ALT as well as AST levels. In both male and female patients, plasma PACAP levels were positively related to L3SMI score. Decreased plasma PACAP levels are linked with disease severity in patients with liver cirrhosis. Reduced plasma PACAP may serve as a biomarker for detection and assessment of the severity of liver cirrhosis.

     

Insulin-like growth factor binding protein-3 in patients with liver cirrhosis

Aim of the study was to evaluate serum levels of insulin-like growth factor binding protein-3 in patients with liver cirrhosis and to compare serum IGFBP-3 levels with other liver function tests. Fifty-one patients with liver cirrhosis were selected for our study. We measured IGFBP-3 (1.67+/-1.06 mg/l, mean+/-SD), albumin (32+/-8 g/l), prealbumin (0.22+/-0.14 g/l), AST (2.29+/-2.38 microkat/l), ALT (2.11+/-4.83 microkat/l) and cholinesterase (mean 78.6+/-45.2 microkat/l) in the serum. There was a significant positive correlation of serum IGFBP-3 with serum albumin and serum cholinesterase. The correlation coefficient was much lower between serum IGFBP-3 and serum prealbumin. There was no significant correlation between serum AST, ALT and IGFBP-3. Serum IGFBP-3 proves to be a better marker for the hepatic synthetic capacity than serum albumin or cholinesterase.     

肝硬化患者肝脏门静脉血流与肝叶萎缩之间关系的研究

目的：探讨肝硬化患者肝脏右叶、左叶体积变化,检测肝硬化患者门静脉血流情况,分析二者之间的关系,以及门静脉血流与肝功能之间关系。方法：本研究纳入54例肝硬化患者和40例正常人,采用超声多普勒方法分析这些受试者的肝脏体积和门静脉主干及左右分支的内径、血流速、流量数据,并通过静脉血检测白蛋白、胆红素、胆碱酯酶水平等评估患者肝功能水平。结果：肝硬化组平均年龄46.3岁,男性32例,其中childA级患者16例,childB级患者27例,childC级患者11例;正常对照组平均年龄41．8岁,男性24例。肝硬化组患者右左肝叶之比明显低于正常对照组（p〈0．05）,门静脉内径和血流量明显高于正常对照组（p〈0．05）．随着child分级升高,门静脉血流量也明显升高。肝硬化组门静脉右支血流量明显低于左支血流量（p〈0．05）;此外肝硬化患者门静脉右支和左支血流量之比明显低于正常人群门静脉右左支之比（p〈0．05）;而且肝硬化患者门静脉右左支血流量之比与右左肝叶具有明显的相关性与右左肝叶之比具有明显的相关性（r=0．64,p〈0．05）。结论：评估肝硬化病人门静脉血流情况,对于判断肝脏病理变化程度,评价治疗效果,以及选择治疗方案方面都具有重要的临床价值     

Bleeding time in patients with hepatic cirrhosis.

OBJECTIVE--To determine the frequency of an abnormal bleeding time in patients with cirrhosis and to relate this to known factors that affect primary haemostasis and to the severity of liver disease. DESIGN--Prospective clinical and laboratory study in patients admitted for complications or investigations of liver disease. SETTING--Royal Free Hospital hepatobiliary and liver transplantation unit. SUBJECTS--100 Consecutive inpatients aged 17-74 with various forms of cirrhosis, including alcoholic, biliary, autoimmune, viral, and cryptogenic. At least 10 days had elapsed since any episodes of bleeding, resolution of sepsis, or alcohol intake. No patient was taking any drug known to affect primary haemostasis. MAIN OUTCOME MEASURES--Bleeding time as measured with the Simplate double blade template device. A bleeding time longer than 10 minutes was considered abnormal. Other measures were platelet count, prothrombin time, partial thromboplastin time, packed cell volume, and blood urea, serum bilirubin, and serum albumin concentrations, all measured on each subject at the same time by standard laboratory methods. RESULTS--A weak but significant correlation existed between the bleeding time and the platelet count (rs = 0.483; p less than 0.001). There were significantly lower platelet counts, longer prothrombin times, and higher blood urea and serum bilirubin concentrations in the 42 patients with bleeding times of 10 minutes or more compared with the 58 patients with bleeding times less than 10 minutes. Multiple linear regression analysis showed that the bilirubin concentration as well as the platelet count was independently correlated with the bleeding time. The combination of a platelet count greater than 80 x 10(9)/l and a prothrombin time less than 17 seconds (usually taken as safe limits for performing routine liver biopsy) did not predict a normal bleeding time. Ten of 39 patients fulfilling these criteria had a prolonged bleeding time. CONCLUSIONS--Prolonged bleeding time is common in patients with cirrhosis, even in those with prothrombin times and platelet counts within "safe limits" for invasive procedures. The severity of liver disease as assessed by the bilirubin concentration plays an important part in determining the bleeding time in cirrhosis. The bleeding time should be measured when assessing patients for invasive procedures who have a raised bilirubin concentration or poor hepatic function, even if the platelet count and prothrombin time are considered adequate.     

Thyroid functions in patients with various chronic liver diseases

In order to clarify an alteration in thyroid functions in patients with chronic liver diseases, serum total and free thyroxine (T4, FT4), total and free triiodothyronine (T3, FT3), total reverse T3 (rT3), thyrotropin (TSH), thyroxine-binding globulin (TBG) concentrations, and T3 uptake (T3U) were measured by radioimmunoassays in 53 patients with chronic hepatitis (CH), 24 patients with compensated liver cirrhosis (LC), 17 patients with hepatocellular carcinoma associated with LC (HCC), and 40 normal subjects. Serum T4, T3, and rT3 in CH, and serum rT3 in HCC were significantly increased, while serum T4 in LC and serum T3 in HCC were significantly decreased. Serum TBG was increased and T3U was decreased in these patients. Serum TBG in CH and LC correlated positively with transaminase, and inversely with prothrombin time. FT4 and T4/TBG ratios in CH and LC and FT3 and T3/TBG ratios in LC and HCC were significantly decreased. Although T4/TBG ratios in HCC and T3/TBG ratios in CH were significantly decreased, FT4 in HCC and FT3 in CH were not decreased. The ratio of rT3/T3 in CH and LC correlated with various liver function tests. FT3 in LC and HCC correlated inversely with BSP (45') and positively with KICG. No differences in serum TSH values were found between chronic liver diseases and normal subjects. From these results, it was concluded that the thyroid functions in patients with chronic liver diseases were affected by the decrease in serum thyroxine, elevated serum TBG, the degree of which is in proportion to that of the liver cell damage, and impaired peripheral conversion of T4 to T3, the degree of which is in proportion to that of the hepatic dysfunction.     

慢性乙型肝炎患者血清白介素17A和胆碱酯酶的表达及临床意义

目的:检测慢性乙型肝炎(CHB)患者血清白介素17A(IL-17A)、胆碱酯酶(CHE)水平,并分析其临床意义。方法:选取2018年1月到2019年3月期间在重庆三峡中心医院接受治疗的CHB患者84例,根据病情严重程度将所有患者分为轻度组30例、中度组28例、重度组26例,另选取同期在重庆三峡中心医院进行体检的健康志愿者50例作为对照组。比较各组的凝血四项指标[纤维蛋白原(FIB)、凝血酶原时间(PT)、凝血活酶时间(APTT)、凝血酶时间(TT)]、肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)]、IL-17A、CHE水平,采用Pearson相关分析CHB患者血清IL-17A、CHE与凝血四项、ALT、AST的相关性。结果:重度组、中度组、轻度组、对照组的FIB、CHE水平逐渐升高,PT、APTT、TT、ALT、AST、IL-17A水平逐渐降低,两两比较均有统计学差异(P0.05),IL-17A与FIB、CHE呈负相关,与PT、APTT、TT、ALT、AST呈正相关(P0.05);CHE与FIB呈正相关,与PT、APTT、TT、ALT、AST呈负相关(P0.05)。结论:CHB患者血清中IL-17A、CHE水平与患者的肝功能和凝血功能密切相关,联合检测IL-17A和CHE有助于患者的病情评估以及预后判断。     

声触诊组织量化技术（VTQ）测量肝硬度与血清AST/ALT比值评价肝硬化患者严重程度及预后分析

摘要 目的：探讨VTQ测量肝硬度与血清AST/ALT比值对肝硬化患者严重程度及预后的评价价值。方法：回顾性选择2018年1月至2022年10月来我院诊治的肝硬化患者80例,根据Child-Pugh分级将80例患者分为Child-Push A级30例、B级25例、C级25级,根据是否存在并发症将80例患者分为并发症组（45例）与非并发症组（35例）,80例患者均用VTQ法检测VTQ值,检测所有患者的血清ALT、AST水平,计算ALT/AST比值。对比不同Child-Push分级患者不同部位的VTQ值,对比不同Child-Push分级患者的AST、ALT水平及AST/ALT比值,对比有无并发症组的不同部位VTQ值,对比有无并发症组患者的AST、ALT水平及AST/ALT比值,分析80例患者不同部位VTQ值与AST、ALT、AST/ALT比值的相关性。结果：C组患者不同肝脏部位的VTQ值明显较A组及B组高,B组患者不同肝脏部位的VTQ值较A组高（P<0.05）。C组的AST水平、AST/ALT值明显较A组、B组高,B组的AST水平、AST/ALT值明显较A组高（P<0.05）,C组的ALT水平较A组、B组高,B组的ALT水平较A组高,但组间对比无统计学意义（P>0.05）。并发症组不同肝脏部位的VTQ值明显较无并发症组高（P<0.05）。并发症组的AST、AST/ALT比值明显较无并发症组高（P<0.05）,并发症组的ALT较无并发症组高,但组间对比无统计学意义（P>0.05）。80例肝硬化患者的AST、AST/ALT比值与不同部位的VTQ值正相关（P<0.05）,ALT水平与不同部位的VTQ值无相关性（P>0.05）。结论：VTQ测量肝硬度与血清AST/ALT比值可用于评价肝硬化严重程度及预后。